David M Davies
Overview
Explore the profile of David M Davies including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obajdin J, Larcombe-Young D, Glover M, Kausar F, Hull C, Flaherty K, et al.
Cell Rep Med
. 2024 Nov;
5(11):101827.
PMID: 39566469
NKG2D ligands (NKG2DLs) are broadly expressed in cancer. To target these, we describe an adaptor chimeric antigen receptor (CAR) termed NKG2D/Dap10-12. Herein, T cells are engineered to co-express NKG2D with...
2.
McPhail D, Alzahrani M, Martin K, Calver B, Harwood A, MacKeigan J, et al.
Res Sq
. 2024 Jul;
PMID: 39070657
Background: Aberrant activation of mTORC1 is clearly defined in TSC, causing uncontrolled cell growth. While mTORC1 inhibitors show efficacy to stabilise tumour growth in TSC, they are not fully curative....
3.
Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner
Hull C, Larcombe-Young D, Mazza R, George M, Davies D, Schurich A, et al.
Mol Ther
. 2024 May;
32(7):2373-2392.
PMID: 38745414
Interleukin (IL)18 is a potent pro-inflammatory cytokine that is activated upon caspase 1 cleavage of the latent precursor, pro-IL18. Therapeutic T cell armoring with IL18 promotes autocrine stimulation and positive...
4.
Davies D, Pugliese G, Parente Pereira A, Whilding L, Larcombe-Young D, Maher J
Biology (Basel)
. 2024 Mar;
13(3).
PMID: 38534465
γδ T-cells provide immune surveillance against cancer, straddling both innate and adaptive immunity. G115 is a clonal γδ T-cell receptor (TCR) of the Vγ9Vδ2 subtype which can confer responsiveness to...
5.
Papa S, Adami A, Metoudi M, Beatson R, George M, Achkova D, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37321663
Background: Locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC) is associated with significant morbidity and mortality. To target upregulated ErbB dimer expression in this cancer, we developed an autologous...
6.
Maher J, Davies D
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831514
Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a...
7.
Maher J, Davies D
Biology (Basel)
. 2023 Feb;
12(2).
PMID: 36829563
Immunotherapy with CAR-engineered immune cells has transformed the management of selected haematological cancers. However, solid tumours have proven much more difficult to control using this emerging therapeutic modality. In this...
8.
Parente-Pereira A, Beatson R, Davies D, Hull C, Whilding L, Porter J, et al.
STAR Protoc
. 2022 May;
3(2):101319.
PMID: 35496793
Clinical trials that tested the antitumor activity of γδ T cells have been mostly unsuccessful. To address this, we expanded human Vγ9Vδ2 T cells in TGFβ1, a cytokine which enhances...
9.
Halim L, Das K, Larcombe-Young D, Ajina A, Candelli A, Benjamin R, et al.
Front Immunol
. 2022 Feb;
13:836549.
PMID: 35222427
Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a...
10.
Beatson R, Parente-Pereira A, Halim L, Cozzetto D, Hull C, Whilding L, et al.
Cell Rep Med
. 2022 Jan;
2(12):100473.
PMID: 35028614
Despite its role in cancer surveillance, adoptive immunotherapy using γδ T cells has achieved limited efficacy. To enhance trafficking to bone marrow, circulating Vγ9Vδ2 T cells are expanded in serum-free...